Japan’s FY 2024 pricing reform expected to favour new listed innovative drugs
At the end of 2023, Japan's Central Social Insurance Medical Council (Chuikyo) approved the outlines of its drug pricing and…
All articles by Chia Lin
Chia Lin
-
-
Reform in South Korea means progression in improving time to reimbursement
South Korea has been busy with a series of reforms that aim to accelerate the time it takes to introduce…
-
Over 2,000 drugs in Japan undergo an average price reduction of 9.4% in April
As of 1 April 2023, Japan’s latest ‘off-year’ National Health Insurance (NHI) drug price revisions for FY2023 have now come…
-
Warnings for Japanese pharmaceutical market may lead to more lenient price controls
Japan is currently the fourth largest market in the world. Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392…